DelveInsight's "Candidemia Pipeline Insight 2023" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Candidemia pipeline landscape. It covers the Candidemia pipeline drug profiles, including Candidemia clinical trials and nonclinical stage products. It also covers the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Candidemia Treatment Landscape
*On
*In
*In
Discover the recent breakthroughs happening in the Candidemia Pipeline landscape @ Candidemia Pipeline Outlook
Key Takeaways from the Candidemia Pipeline Report
*DelveInsight's Candidemia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Candidemia treatment.
*The leading Candidemia Companies include
*Promising Candidemia Pipeline Therapies include ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others
*The Candidemia companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The Candidemia therapies under development are focused on novel approaches to treat/improve Candidemia.
Candidemia Emerging Drugs Profile
*Rezafungin:
Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. For the treatment of candidemia and invasive candidiasis, rezafungin has designations for Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in
Get More Information on the Candidemia Drugs and Companies of Report @ Candidemia Ongoing Clinical Trials Analysis
Scope of the Candidemia Pipeline Report
*Coverage- Global
*Candidemia Companies-
*Candidemia Pipeline Therapies- ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others.
*Candidemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Find out more about the list of FDA-approved drugs for Candidemia @ Candidemia Treatment Landscape
Table of Content
*Introduction *Executive Summary *Candidemia: Overview *Pipeline Therapeutics *Therapeutic Assessment *Late Stage Products (Phase III) *Rezafungin:
Got Queries? Find out the related information on Candidemia Preclinical and Discovery Stage Products @ Candidemia Drugs, Unmet Needs, and Recent Trends
About Us
DelveInsight is a
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: +91 9568243403
Address:
City:
State: NV
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2023 M2 COMMUNICATIONS, source